Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 314Terminated 78Recruiting 60Active not recruiting 35Withdrawn 22Unknown 21Not yet recruiting 4Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 47Breast Neoplasms 46Colorectal Neoplasms 28Prostatic Neoplasms 26Carcinoma, Non-Small-Cell Lung 21Leukemia, Myeloid, Acute 19Glioblastoma 19Pancreatic Neoplasms 17Melanoma 17Lung Neoplasms 17Neoplasm Metastasis 16Glioma 14Stomach Neoplasms 13Carcinoma, Hepatocellular 13Brain Neoplasms 13Ovarian Neoplasms 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Triple Negative Breast Neoplasms 10Multiple Myeloma 10Head and Neck Neoplasms 10Carcinoma, Renal Cell 10Lymphoma 9Uterine Cervical Neoplasms 7Rectal Neoplasms 7Hematologic Neoplasms 7Esophageal Neoplasms 7Colonic Neoplasms 7Sarcoma 6Leukemia 6

Interventions

eltrombopag 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Leukemia, Myelomonocytic, Chronic × Clear all
NCT06630221 2026-06-05

Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

Case Comprehensive Cancer Center

Phase 2 Suspended
25 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡